Skip to content
DataLookout
Menu

NCT06618391

Local Injection and Systemic Therapy in the Treatment of NSCLC.

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

lung recruitment rate
Timeframe: every 3 weeks during intratumoral treatment in the first two cycles,At the end of Cycle 1and Cycle2 (each cycle is 281days).

Secondary (6)

ORR(Objective response rate)
DCR(Disease control rate)
PFS(Progression-free survival)
OS(Overall survival)
RFS(Recurrence free survival)
Show 1 moreShow less
EORTC QLQ-C30 scale

Arms and interventions

EnvafolimabExperimental

Envafolimab 150 mg Q3W (maximum 2 cycles of intratumoral therapy) was injected intratumorally on days 1 and 8, combined with chemotherapy + Recombinant human endostatin Q3W for 4-6 cycles;

Recombinant human endostatinExperimental

Intratumoral injection of Recombinant human endostatin15mg Q3W (maximum 2 cycles of intratumoral therapy) on Days 1 and 8; combined chemotherapy + Enbrelizumab Q3W for 4-6 cycles.

Recombinant human adenovirus type 5Experimental

1.0 ml of recombinant human adenovirus type 5 injected intratumorally on days 1 and 8, Q3W (maximum 2 cycles of intratumoral therapy); combined chemotherapy + envolumab, Q3W, 4-6 cycles of treatment.

Drugs: Envafolimab, Recombinant human endostatin, recombinant human adenovirus type 5